Compare iShares MSCI Malaysia ETF (EWM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Malaysia ETF vs Sana Biotechnology Inc — how do they compare? iShares MSCI Malaysia ETF trades at $28.28, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: iShares MSCI Malaysia ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| EWM | SANA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $5.92 |
52-Week Low | $24.73 | $2.68 |
Market Cap | — | $1.13B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWM, the iShares MSCI Malaysia ETF, trades at $28.28, up 0.86% today, with a bearish technical signal from moving averages and oscillators neutral. The ETF is heavily weighted in Financials (54%) and Industrials (21%). Recent news highlights Malaysia's data center expansion, semiconductor ambitions, and tourism initiatives as growth drivers, though the country faces energy supply challenges amid rising power demand.
Outlook is mixed: Malaysia's economic initiatives offer potential upside, but energy constraints and concentrated sector exposure pose risks. The ETF provides targeted emerging market access, with investor sentiment cautious due to macroeconomic uncertainties and technical weakness.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
